Cagrilintide: Benefits & Research
Part of the Cagrilintide Complete Guide
Research Peptides
Advertiser link — we may earn a commission at no extra cost to you.
Weight Loss
Cagrilintide monotherapy (4.5 mg) produced approximately 10.8% body weight loss over 26 weeks in Phase 2 trials. The CagriSema combination (cagrilintide + semaglutide) demonstrated up to 22.7% weight loss — exceeding either agent alone and representing one of the largest pharmaceutical weight loss results achieved.
Satiety & Appetite Control
Cagrilintide promotes satiety through amylin receptor activation in the area postrema and nucleus tractus solitarius — brain regions that regulate fullness and food intake. This mechanism is distinct from and complementary to GLP-1 signaling, explaining the additive effect in CagriSema.
Metabolic Improvements
Clinical trials show cagrilintide improves glucose homeostasis, reduces HbA1c, and improves insulin sensitivity. The amylin pathway also slows gastric emptying and suppresses inappropriate postprandial glucagon release.